Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

A Randomised, Double-blind, Placebo-controlled, Crossover Pilot Study to Define the High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.

Inclusion Criteria:

• Signed informed consent
• males aged 45-65
• insulin resistance
• central obesity
• LDL-C <6 mmol/L
• plasma triglycerides >=1.7 and ≤5.5 mmol/L
• HDL-C ≤1.2 mmol/L.

Exclusion Criteria:

• total cholesterol >7mmol/L
• pre-existing cardiovascular disease, diabetes, proteinuria or renal failure